Jump to content

Recruiting now: Combined trial of Xofigo (Radium-223) and Zytiga (Abiraterone Acetate), including Australia


Recommended Posts

Bayer announced a new trial has started recruiting combining Xofigo and Zytiga for men with metastatic castration-resistant cancer.


Both Xofigo (Radium-223) and Zytiga (Abiraterone Acetate) have been shown in separate trials to both prolong life and give a higher quality of life.


The trial will be available to men in a number of countries, including Australia. Specific sites are not yet listed in ClinicalTrials.gov (as of 9 April 2014).


However, in a press release dated 2 April 2014, the company said:


Bayer HealthCare today announced that the company has begun to enroll patients in a new Phase III trial with radium-223 dichloride (radium-223, Xofigo®). The study evaluates radium-223 in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (CRPC). 


If you may be interested in this trial, your doctor will have to contact Bayer for details of Australian participants.


The trial is titled:

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms


It can be found here:



or by searching for NCT02043678

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...